Synthesis of Novel N(4)-Hydrocytidine Analogs as Potential Anti-SARS-CoV-2 Agents

Coronavirus disease 2019 (COVID-19) is an emerging global pandemic with severe morbidity and mortality caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Molnupiravir, an ester prodrug form of N(4)-hydroxycytidine (NHC), was recently emergency-use approved for the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Amblard, Franck, LeCher, Julia C., De, Ramyani, Goh, Shu Ling, Li, Chengwei, Kasthuri, Mahesh, Biteau, Nicolas, Zhou, Longhu, Tber, Zahira, Downs-Bowen, Jessica, Zandi, Keivan, Schinazi, Raymond F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504122/
https://www.ncbi.nlm.nih.gov/pubmed/36145365
http://dx.doi.org/10.3390/ph15091144
_version_ 1784796136525004800
author Amblard, Franck
LeCher, Julia C.
De, Ramyani
Goh, Shu Ling
Li, Chengwei
Kasthuri, Mahesh
Biteau, Nicolas
Zhou, Longhu
Tber, Zahira
Downs-Bowen, Jessica
Zandi, Keivan
Schinazi, Raymond F.
author_facet Amblard, Franck
LeCher, Julia C.
De, Ramyani
Goh, Shu Ling
Li, Chengwei
Kasthuri, Mahesh
Biteau, Nicolas
Zhou, Longhu
Tber, Zahira
Downs-Bowen, Jessica
Zandi, Keivan
Schinazi, Raymond F.
author_sort Amblard, Franck
collection PubMed
description Coronavirus disease 2019 (COVID-19) is an emerging global pandemic with severe morbidity and mortality caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Molnupiravir, an ester prodrug form of N(4)-hydroxycytidine (NHC), was recently emergency-use approved for the treatment of early SARS-CoV-2 infections. Herein, we report the synthesis and evaluation of a series of novel NHC analogs.
format Online
Article
Text
id pubmed-9504122
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95041222022-09-24 Synthesis of Novel N(4)-Hydrocytidine Analogs as Potential Anti-SARS-CoV-2 Agents Amblard, Franck LeCher, Julia C. De, Ramyani Goh, Shu Ling Li, Chengwei Kasthuri, Mahesh Biteau, Nicolas Zhou, Longhu Tber, Zahira Downs-Bowen, Jessica Zandi, Keivan Schinazi, Raymond F. Pharmaceuticals (Basel) Article Coronavirus disease 2019 (COVID-19) is an emerging global pandemic with severe morbidity and mortality caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Molnupiravir, an ester prodrug form of N(4)-hydroxycytidine (NHC), was recently emergency-use approved for the treatment of early SARS-CoV-2 infections. Herein, we report the synthesis and evaluation of a series of novel NHC analogs. MDPI 2022-09-14 /pmc/articles/PMC9504122/ /pubmed/36145365 http://dx.doi.org/10.3390/ph15091144 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Amblard, Franck
LeCher, Julia C.
De, Ramyani
Goh, Shu Ling
Li, Chengwei
Kasthuri, Mahesh
Biteau, Nicolas
Zhou, Longhu
Tber, Zahira
Downs-Bowen, Jessica
Zandi, Keivan
Schinazi, Raymond F.
Synthesis of Novel N(4)-Hydrocytidine Analogs as Potential Anti-SARS-CoV-2 Agents
title Synthesis of Novel N(4)-Hydrocytidine Analogs as Potential Anti-SARS-CoV-2 Agents
title_full Synthesis of Novel N(4)-Hydrocytidine Analogs as Potential Anti-SARS-CoV-2 Agents
title_fullStr Synthesis of Novel N(4)-Hydrocytidine Analogs as Potential Anti-SARS-CoV-2 Agents
title_full_unstemmed Synthesis of Novel N(4)-Hydrocytidine Analogs as Potential Anti-SARS-CoV-2 Agents
title_short Synthesis of Novel N(4)-Hydrocytidine Analogs as Potential Anti-SARS-CoV-2 Agents
title_sort synthesis of novel n(4)-hydrocytidine analogs as potential anti-sars-cov-2 agents
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504122/
https://www.ncbi.nlm.nih.gov/pubmed/36145365
http://dx.doi.org/10.3390/ph15091144
work_keys_str_mv AT amblardfranck synthesisofnoveln4hydrocytidineanalogsaspotentialantisarscov2agents
AT lecherjuliac synthesisofnoveln4hydrocytidineanalogsaspotentialantisarscov2agents
AT deramyani synthesisofnoveln4hydrocytidineanalogsaspotentialantisarscov2agents
AT gohshuling synthesisofnoveln4hydrocytidineanalogsaspotentialantisarscov2agents
AT lichengwei synthesisofnoveln4hydrocytidineanalogsaspotentialantisarscov2agents
AT kasthurimahesh synthesisofnoveln4hydrocytidineanalogsaspotentialantisarscov2agents
AT biteaunicolas synthesisofnoveln4hydrocytidineanalogsaspotentialantisarscov2agents
AT zhoulonghu synthesisofnoveln4hydrocytidineanalogsaspotentialantisarscov2agents
AT tberzahira synthesisofnoveln4hydrocytidineanalogsaspotentialantisarscov2agents
AT downsbowenjessica synthesisofnoveln4hydrocytidineanalogsaspotentialantisarscov2agents
AT zandikeivan synthesisofnoveln4hydrocytidineanalogsaspotentialantisarscov2agents
AT schinaziraymondf synthesisofnoveln4hydrocytidineanalogsaspotentialantisarscov2agents

Ejemplares similares